Dietary supplements for body-weight reduction: A systematic review

American Journal of Clinical Nutrition

Volumn 79, Issue 4, 2004, Pages 529-536

  Pittler, Max H ^a   Ernst, Edzard ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Alternative medicine; Chitosan; Chromium; Complementary medicine; Dietary supplements; Ephedra; Garcinia; Guar; Herbal medicine; Obesity; Overweight; Psyllium; Weight reduction

Indexed keywords

BUTYRIC ACID DERIVATIVE; CHITOSAN; CHROMIUM PICOLINATE; EPHEDRA SINICA EXTRACT; GUAR GUM; HYDROXYMETHYLBUTYRATE; ISPAGULA; MANNAN; PYRUVIC ACID; UNCLASSIFIED DRUG;

COCHRANE LIBRARY; DIET SUPPLEMENTATION; EMBASE; HUMAN; ILEX PARAGUARIENSIS; LITERATURE; MEDLINE; METHODOLOGY; PUBLICATION; RANDOMIZATION; REVIEW; SCREENING; SYSTEMATIC REVIEW; VALIDATION PROCESS; WEIGHT REDUCTION; ALTERNATIVE MEDICINE; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; META ANALYSIS; OBESITY; RANDOMIZED CONTROLLED TRIAL; STANDARD; UNITED STATES;

CROTON OVALIFOLIUS; CYAMOPSIS TETRAGONOLOBA; EPHEDRA; EPHEDRA SINICA; GARCINIA; GARCINIA CAMBOGIA; PLANTAGO PSYLLIUM;

COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; HUMANS; META-ANALYSIS; OBESITY; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; WEIGHT LOSS;

EID: 2142655783     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/79.4.529     Document Type: Review

References (80)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults 1999-2000. JAMA 2002;288:1723-7.
2. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2002;360:861-8.
3. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001;161:1581-6.
4. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity and health risk. Arch Intern Med 2000;160:898-904.
5. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13.
6. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization, 1998.
7. Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? Br Med J 1995;311:437-9.
8. Heini AF, Weinsier RL. Divergent trends in obesity and fat intake patterns: the American paradox. Am J Med 1997;102:259-64.
9. Blanck HM, Khan LK, Serdula MK. Use of nonprescription weight loss products. Results of a multistate survey. JAMA 2001;286:930-5.
10. Miles J, Petrie C, Steel M. Slimming on the internet. J R Soc Med 2000;93:254-7.
11. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 2002;31:123-4.
12. Jadad AR, Moore RA, Carrol D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
13. Paranjpe P, Patki P, Patwardhan B. Ayurvedic treatment of obesity: a randomised double-blind, placebo-controlled clinical trial. J Ethnopharmacol 1990;29:1-11.
14. Wuolijoki E, Hirvelä T, Ylitalo P. Decrease in serum LDL cholesterol with microcrystalline chitosan. Methods Find Exp Clin Pharmacol 1999;21:357-61.
15. Schiller RN, Barrager E, Schauss AG, Nichols EJ. A randomized, double-blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. J Am Nutraceut Assn 2001;4:42-9.
16. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomised, double blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999;53:379-81.
17. Ho SC, Tai ES, Eng PHK, Tan CE, Fok ACK. In the absence of dietary surveillance chitosan does not reduce plasma lipids or obesity in hypercholesterolaemic obese Asian subjects. Singapore Med J 2001;42:6-10.
18. Girola M, De Bernardi M, Contos S, et al. Dose effect in lipid-lowering activity of a new dietary integrator (Chitosan, Garcinia cambogia extract and chrome). Acta Toxicol Ther 1996;17:25-40.
19. Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. Diabet Obes Metab 1999;1:331-7.
20. Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential anti-obesity agent. JAMA 1998;280:1596-600.
21. Mattes RD, Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. Physiol Behav 2000;71:87-94.
22. Thom E. Hydroxycitrate (HCA) in the treatment of obesity. Int J Obes Relat Metab Disord 1996;20(suppl):75 (abstr).
23. Rothacker DQ, Waitman BE. Effectiveness of a Garcinia cambogia and natural caffeine combination in weight loss - a double-blind, placebo-controlled pilot study. Int J Obes Relat Metab Disord 1997;21 (suppl):53 (abstr).
24. Antonio J, Colker CM, Torina GC, Shi Q, Brink W, Kalman D. Effects of a standardized guggulsterone phosphate supplement on body composition in overweight adults: a pilot study. Curr Ther Res 1999;60:220-7.
25. Thom E. A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. J Int Med Res 2000;28:229-33.
26. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1983;8:289-93.
27. Nissen S, Panton L, Wilhelm R, Fuller JC Jr. Effect of β-hydroxy-β-methylbutyrate (HMB) supplementation on strength and body composition of trained and untrained males undergoing intense resistance training. FASEB J 1996;10:A287 (abstr).
28. Vukovich MD, Stubbs NB, Bohlken RM, Desch MF, Fuller JC Jr, Rathmacher JA. The effect of dietary β-hydroxy-β-methylbutyrate (HMB) on strength gains and body composition changes in older adults. FASEB J 1997;11:A376 (abstr).
29. Rodríguez-Morán M, Guerrero-Romero F, Laczano-Burciaga. Lipid-and glucose-lowering efficacy of plantago psyllium in type II diabetes. J Diabetes Complications 1998;12:273-8.
30. Kalman D, Colker CM, Wilets I, Roufs JB, Antonio J. The effects of pyruvate supplementation on body composition in overweight individuals. Nutrition 1999;15:337-40.
31. Kalman D, Colker CM, Stark R, Minsch A, Wilets I, Antonio J. Effects of pyruvate supplementation on body composition and mood. Curr Ther Res 1998;59:793-802.
32. Andersen T, Fogh J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J Hum Nutr Dietet 2001;14:243-50.
33. Kucio C, Jonderko K, Piskorska D. Does yohimbine act as a slimming drug? Isr J Med Sci 1991;27:550-6.
34. Sax L. Yohimbine does not affect fat distribution in men. Int J Obes 1991;15:561-5.
35. Berlin I, Stalla-Bourdillon A, Thuillier Y, Turpin G, Puech J. Lack of efficacity of yohimbine in the treatment of obesity. J Pharmacol (Paris) 1986;17:343-7.
36. Ernst E, Pittler MH. Chitosan as a treatment for body weight reduction? Perfusion 1998;11:461-5.
37. Pittler MH, Stevinson C, Ernst E. Chromium picolinate for body weight reduction. Meta-analysis of randomized trials. Int J Obes Relat Metab Disord 2003;27:522-9.
38. Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001;2:199-211.
39. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance. JAMA 2003;289:1537-45.
40. Pittler MH, Ernst E. Guar gum for body weight reduction. Meta-analysis of randomized trials. Am J Med 2001;110:724-30.
41. Kanauchi O, Deuchi K, Imasato Y, Shizukuishi M, Kobayashi E. Mechanism for the inhibition of fat digestion by chitosan and for the synergistic effect of ascorbate. Biosci Biotech Biochem 1995;59:786-90.
42. Nauss JL, Thompson JL, Nagyuvary J. The binding of micellar lipids to chitosan. Lipids 1983;18:714-9.
43. Nagyvary JJ, Falk JD, Hill ML, Schmidt ML, Wilkins AK, Bradbury EL. The hypolipidemic activity of chitosan and other polysaccharides in rats. Nutr Rep Int 1979;20:677-84.
44. Vahouny GV, Satchithanandam S, Cassidy MM, Lightfood FB, Fzirda I. Comparative effects of chitosan and cholestyramine on lymphatic absorption of lipids in the rat. Am J Clin Nutr 1983;38:278-84.
45. Anderson RA. Effects of chromium on body composition and weight loss. Nutr Rev 1998;56:266-70.
46. Offenbacher EG, Pi-Sunyer FX. Chromium in human nutrition. Annu Rev Nutr 1988;8:543-63.
47. Mertz W. Chromium in human nutrition: a review. J Nutr 1993;123:626-33.
48. Anderson RA. Essentiality of chromium in humans. Sci Total Environ 1989;86:75-81.
49. Cowburn G, Hillsdon M, Hankey CR. Obesity management by life-style strategies. Br Med Bull 1997;53:389-408.
50. Blumenthal M, Goldberg A, Brinckmann J. Herbal medicine. Expanded commission E monographs. Austin, TX: American Botanical Council, 2000.
51. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8.
52. Fontanarosa PB, Rennie D, DeAngelis CD. The need for regulation of dietary supplements - lessons from ephedra. JAMA 2003;289:1568-70.
53. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr 1995;49(suppl):S190-7.
54. Nissen S, Sharp R, Ray M, et al. Effect of leucine metabolite β-hydroxy-β-methylbutyrate on muscle metabolism during resistance-exercise training. J Appl Physiol 1996;81:2095-104.
55. Stanko RT, Reynolds HR, Hoyson R, Janosky JE, Wolf R. Pyruvate supplementation of a low-cholesterol, low-fat diet: effects on plasma lipid concentrations and body composition in hyperlipidemic patients. Am J Clin Nutr 1994;59:423-7.
56. Stanko RT, Arch JE. Inhibition of regain of body weight and fat with addition of 3-carbon compounds to the diet with hyperenergetic refeeding after weight reduction. Int J Obes Relat Metab Disord 1996;20:925-30.
57. Allison DB, Fontaine KR, Heshka S, Mentore JL, Heymsfield SB. Alternative treatments for weight loss: a critical review. Crit Rev Food Sci Nutr 2001;41:1-28.
58. Arterburn D, Hitchcock Noël P. Obesity. BMJ 2001;322:1406-9.
59. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003;289:1805-12.
60. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements. Med J Aust 1999;171:604-8.
61. Hosobuchi, C, Rutanassee L, Bassin S-L, Wong N-D. Efficacy of acacia, pectin and guar gum-based fiber supplementation in the control of hypercholesterolaemia. Nutr Res 1999;19:643-9.
62. Najemnik C, Kritz H, Irsigler K, et al. Guar and its effects on metabolic control in type II diabetic patients. Diabetes Care 1984;7:215-20.
63. Wirth A, Middlehoff G, Braeunig C, Schlierf G. Treatment of familial hypercholesterolaemia with a combinations of bezafibrate and guar. Atherosclerosis 1982;45:291-7.
64. Hänsel R, Keller K, Rimpler H, Schneider G, eds. Hagers Handbuch der pharmazeutischen Praxis. Berlin: Springer, 1992.
65. Stearns DM, Wise JP, Patierno SR, Wetterhahn KE. Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J 1995;9:1643-8.
66. Anderson RA, Bryden NA, Polansky NN. Lack of toxicity of chromium chloride and chromium picolinate in rats. J Am Coll Nutr 1997;16:273-9.
67. Kato I, Vogelman JH, Karkoszka J, et al. Effect of supplementation with chromium picolinate on antibody titers to 5-hydroxymethyl uracil. Eur J Epidemiol 1998;14:621-6.
68. Hepburn DDD, Xiao J, Bindon S, Vincent JB, O'Donnell J. Nutritional supplement chromium picolinate causes sterility and lethal mutations in Drosophila melanogaster. Proc Natl Acad Sci U S A 2003;100:3766-71.
69. Martin WR, Fuller R. Suspected chromium picolinate-induced rhabdomyolysis. Pharmacotherapy 1998;18:860-2.
70. Scroggie DA, Harris M, Sakai L. Rhabdomyolysis associated with nutritional supplement use. J Clin Rheumatol 2000;6:328-32.
71. Cerulli J, Grabe DW, Gauthier I, Malone M, McGoldrick MD. Chromium picolinate toxicity. Ann Pharmacother 1998;32:428-31.
72. Young PC, Turiansky GW, Bonner MW, Benson PM. Acute generalizedexanthematous pustulosis induced by chromium picolinate. J Am Acad Dermatol 1999;41:820-3.
73. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263:1385-9.
74. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867-72.
75. Egger M, Davey Smith G. Bias in location and selection of studies. BMJ 1998;316:61-6.
76. Ernst E, Pittler MH. Alternative therapy bias. Nature 1997;385:480 (letter).
77. Schmidt K, Pittler MH, Ernst E. Bias in alternative medicine is still rife but is diminishing. BMJ 2001;323:1071 (letter).
78. Pittler MH, Abbot NC, Harkness EF, Ernst E. Location bias in controlled clinical trials of complementary/alternative therapies. J Clin Epidemiol 2000;53:485-9.
79. Egger M, Zelhveger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-9.
80. Nieminen P, Isohanni M. Bias against European journals in medical publication databases. Lancet 1999;353:1592 (letter).